Terlipressin: complete guide

Terlipressin is a synthetic vasopressin analog approved by FDA as Terlivaz in 2022 for hepatorenal syndrome. This guide covers its structure, mechanism, labeled use, trials and warnings.

Complete guide5 min read

Key takeaway

FDA approved terlipressin as Terlivaz on September 14, 2022. PubChem lists a molecular weight of 1,227.4 g/mol. In the CONFIRM trial, verified reversal of hepatorenal syndrome occurred in 32% of terlipressin patients versus 17% on placebo. Deaths within 90 days from respiratory disorders were 11% versus 2%.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Terlivaz on September 14, 2022.” (this article)
ClassHeart & blood
Body systemsHeart & vessels
Studies cited3 in this article · 3 across 1 article on Terlipressin
Related productsResearch peptide catalog

Terlipressin is a 12-amino-acid synthetic analog of vasopressin, the body’s antidiuretic hormone. In the United States it is approved for hepatorenal syndrome, a kidney complication of advanced liver disease such as cirrhosis. This guide covers its structure, mechanism, labeled use, trials and boxed warning. Sources were checked on November 17, 2026.

Quick answer: Terlipressin is a prescription vasopressin analog sold as Terlivaz. Its label covers improving kidney function in adults with hepatorenal syndrome with rapid loss of kidney function. It carries a boxed warning that it may cause serious or fatal respiratory failure. Other warnings cover ischemic events and loss of liver transplant eligibility.

Vitrapep does not sell terlipressin; this page is a reference summary of published research and regulatory information.

What is terlipressin?

The Terlivaz label states that it “contains terlipressin, a vasopressin receptor agonist.” It describes terlipressin as “a 12-amino acid peptide” and as “a synthetic vasopressin analogue” (Terlivaz label, 2026). Natural vasopressin, by contrast, is a nonapeptide of nine amino acids. MeSH calls it “the predominant form of mammalian antidiuretic hormone” (PubChem CID 644077). NCI Thesaurus text in PubChem describes terlipressin as “a synthetic triglycyllysine derivative of vasopressin” (PubChem CID 72081). Our vasopressin guide covers the parent hormone.

The label also explains that terlipressin “acts as both a prodrug for lysine-vasopressin, as well as having pharmacologic activity on its own.” A prodrug is converted in the body into an active form. PubChem lists the formula as C52H74N16O15S2 and the molecular weight as 1,227.4 g/mol (PubChem CID 72081). The label gives an average of 1,227.38 for the free base.

Drugs@FDA lists the original approval of Terlivaz (NDA 022231) on September 14, 2022, to Mallinckrodt Ireland (Drugs@FDA). The current DailyMed label names Keenova Hospital Products Inc. as labeler. For background on peptide drugs, see what peptides are.

Table 1

Terlipressin: key facts

Fact Detail
Structure type Synthetic 12-amino-acid peptide; vasopressin analog and prodrug of lysine-vasopressin
Class Vasopressin receptor agonist
Molecular formula C52H74N16O15S2
Molecular weight 1,227.4 g/mol
First FDA approval September 14, 2022 (Terlivaz, NDA 022231)
Brand names (US) Terlivaz

How does terlipressin work?

The label calls terlipressin a vasopressin analog “with twice the selectivity for vasopressin V1 receptors versus V2 receptors.” NCI Thesaurus text in PubChem explains the split. As a V1 agonist, terlipressin “increases systemic vascular resistance, particularly in the splanchnic area,” the blood supply of the gut. It has minimal effect on V2 receptors, which drive water reabsorption in the kidney.

The label states that terlipressin “is thought to increase renal blood flow in patients with hepatorenal syndrome by reducing portal hypertension.” It does this by lowering blood circulation in the portal vessels. It also increases effective arterial volume and mean arterial pressure (Terlivaz label, 2026).

What is terlipressin approved for?

The Terlivaz label states: “TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.”

It adds a limitation of use: patients with very high serum creatinine at the start are unlikely to benefit. Creatinine is a blood marker of kidney function.

What did the key trials show?

CONFIRM. The pivotal human trial was a phase 3, randomized, double-blind, placebo-controlled study. It randomized 300 adults with type 1 hepatorenal syndrome two to one: 199 to terlipressin and 101 to placebo. Albumin was strongly recommended in both groups.

The primary end point was verified reversal of hepatorenal syndrome. That meant two low creatinine readings at least 2 hours apart, plus survival without dialysis for at least 10 days after treatment. Verified reversal occurred in 32% of terlipressin patients and 17% on placebo (P = 0.006). However, death within 90 days from respiratory disorders occurred in 11% versus 2% (Wong et al., 2021). The label’s analysis reports 29.1% versus 15.8% (P = 0.012). The registry record is NCT02770716.

Earlier trials. Two earlier randomized, placebo-controlled human trials did not meet their primary end points. In a 2008 trial of 112 patients, treatment success was 25% versus 12.5% (P = .093) (Sanyal et al., 2008). In a 2016 trial of 196 patients, confirmed reversal was 19.6% versus 13.1% (P = .22) (Boyer et al., 2016; NCT01143246). Both found falls in creatinine that favored terlipressin.

What side effects does the label list?

The Terlivaz label carries a boxed warning. It states that “TERLIVAZ may cause serious or fatal respiratory failure.” Patients with volume overload or with grade 3 acute-on-chronic liver failure are at increased risk. The label calls for monitoring of oxygen levels during treatment.

The label lists the most common adverse reactions, each 10% or more. Rates in the trial, Terlivaz versus placebo, were:

  • Abdominal pain: 19.5% versus 6.1%
  • Nausea: 16.0% versus 10.1%
  • Respiratory failure: 15.5% versus 7.1%
  • Diarrhea: 13.0% versus 7.1%
  • Dyspnea (shortness of breath): 12.5% versus 5.1%

Other warnings cover ischemic events and embryo-fetal toxicity. The label states that it “may cause cardiac, cerebrovascular, peripheral, or mesenteric ischemia,” meaning reduced blood supply to the heart, brain, limbs or gut. It also warns that reactions such as respiratory failure or ischemia may make a listed patient ineligible for a liver transplant (Terlivaz label, 2026).

What is terlipressin’s regulatory status, and how is it used in research?

Terlipressin is a prescription drug in the United States. Drugs@FDA lists Terlivaz as a prescription product, and the label on DailyMed was revised in September 2026. Terlivaz is the only terlipressin label on DailyMed when we checked.

The evidence summarized here comes from human trials in hepatorenal syndrome. We found no documented role for terlipressin as a routine laboratory reagent in the sources we checked.

Frequently asked questions about terlipressin

Is terlipressin a peptide?

Yes. The label calls it a 12-amino-acid peptide and a synthetic vasopressin analog.

When was terlipressin approved in the United States?

Drugs@FDA lists the original approval of Terlivaz on September 14, 2022.

How is terlipressin different from vasopressin?

Terlipressin has 12 amino acids to vasopressin’s nine. It favors V1 receptors two to one and works partly as a prodrug of lysine-vasopressin.

Why does terlipressin have a boxed warning?

It may cause serious or fatal respiratory failure. In CONFIRM, deaths within 90 days from respiratory disorders were 11% with terlipressin versus 2% with placebo.

Did terlipressin improve survival?

The trials summarized here measured kidney function as the main outcome. The 2008 and 2016 trials found similar overall survival between groups.

What to know now

  • Structure: synthetic 12-amino-acid vasopressin analog; C52H74N16O15S2; 1,227.4 g/mol.
  • Approval: Terlivaz, September 14, 2022; prescription only.
  • Mechanism: V1-leaning vasopressin agonist and prodrug of lysine-vasopressin.
  • Label use: improving kidney function in adults with hepatorenal syndrome with rapid loss of function.
  • Evidence: verified reversal 32% versus 17% in CONFIRM.
  • Safety: boxed warning for serious or fatal respiratory failure.

What we’re watching

Further Terlivaz label revisions on DailyMed, most recently in September 2026. Related guides: vasopressin, desmopressin and angiotensin II.

More for heart & vessels

All 13 compounds for heart & vessels

Sources: Keenova Hospital Products Inc 2026, TERLIVAZ (terlipressin) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 022231 (TERLIVAZ) . Retrieved November 17, Drugs@FDA: NDA 022231 (TERLIVAZ); National Center for Biotechnology Information 2026, PubChem compound summary for CID 72081, terlipressin; National Center for Biotechnology Information 2026, PubChem compound summary for CID 644077, argipressin; Wong 2021, The New England Journal of Medicine, 384; Mallinckrodt 2016; Sanyal 2008, Gastroenterology, 134; Boyer 2016, Gastroenterology, 150; Mallinckrodt 2010. All 9 citations

Back to the research library

References

  1. Keenova Hospital Products Inc. (2026). TERLIVAZ (terlipressin) prescribing information (revised 9/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a35b86c-f451-4fac-8499-43019e4da354
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 022231 (TERLIVAZ). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022231
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 72081, terlipressin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/72081
  4. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 644077, argipressin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/644077
  5. Wong, F., et al. (2021). Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. The New England Journal of Medicine, 384(9), 818-828. https://doi.org/10.1056/NEJMoa2008290
  6. Mallinckrodt. (2016). Study to confirm efficacy and safety of terlipressin in hepatorenal syndrome (HRS) type 1 (CONFIRM) (ClinicalTrials.gov ID NCT02770716). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02770716
  7. Sanyal, A. J., et al. (2008). A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology, 134(5), 1360-1368. https://doi.org/10.1053/j.gastro.2008.02.014
  8. Boyer, T. D., et al. (2016). Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology, 150(7), 1579-1589.e2. https://doi.org/10.1053/j.gastro.2016.02.026
  9. Mallinckrodt. (2010). A placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin (ClinicalTrials.gov ID NCT01143246). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01143246